Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo de Marinis

Showing results (1-10 of 334) with videos related to

Pageof 34
Sort By:
Reviews on Recent Clinical Trials|December 24, 2009
Treatment of bone metastases in lung cancer: the actual role of zoledronic acidSerena Ricciardi, Filippo de Marinis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2014
Afatinib-related nonhematologic adverse events: is common evaluation enough for now?Filippo de Marinis, Antonio Passaro
Tumori|December 31, 2008
[Role of pemetrexed in the treatment of advanced non-small-cell lung cancer: news from ASCO, 2008]Filippo de Marinis, Serena Ricciardi
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
Second-line treatment options in advanced non-small cell lung cancerFilippo de Marinis, Serena Ricciardi
Translational Lung Cancer Research|February 11, 2020
Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpointsAntonio Passaro, Filippo de Marinis
Translational Lung Cancer Research|May 22, 2018
Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken optionAntonio Passaro, Filippo de Marinis
Oncology|February 5, 2010
New agents in advanced non-small-cell lung cancer treatmentSerena Ricciardi, Filippo de Marinis
Annals of Palliative Medicine|April 6, 2015
Expectations as outcome of effectiveness for patients with metastatic lung cancerAntonio Passaro, Filippo de Marinis
The Oncologist|March 8, 2008
Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancerFilippo de Marinis, Francesco Grossi
Recenti Progressi in Medicina|December 21, 2016
[Nivolumab in second-line treatment of squamous non-small cell lung cancer.]Filippo De Marinis, Antonio Passaro
Pageof 34

Showing results (1-10 of 334) with videos related to

Sort By:
Pageof 34
Reviews on Recent Clinical Trials|December 24, 2009
Treatment of bone metastases in lung cancer: the actual role of zoledronic acidSerena Ricciardi, Filippo de Marinis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2014
Afatinib-related nonhematologic adverse events: is common evaluation enough for now?Filippo de Marinis, Antonio Passaro
Tumori|December 31, 2008
[Role of pemetrexed in the treatment of advanced non-small-cell lung cancer: news from ASCO, 2008]Filippo de Marinis, Serena Ricciardi
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
Second-line treatment options in advanced non-small cell lung cancerFilippo de Marinis, Serena Ricciardi
Translational Lung Cancer Research|February 11, 2020
Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpointsAntonio Passaro, Filippo de Marinis
Translational Lung Cancer Research|May 22, 2018
Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken optionAntonio Passaro, Filippo de Marinis
Oncology|February 5, 2010
New agents in advanced non-small-cell lung cancer treatmentSerena Ricciardi, Filippo de Marinis
Annals of Palliative Medicine|April 6, 2015
Expectations as outcome of effectiveness for patients with metastatic lung cancerAntonio Passaro, Filippo de Marinis
The Oncologist|March 8, 2008
Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancerFilippo de Marinis, Francesco Grossi
Recenti Progressi in Medicina|December 21, 2016
[Nivolumab in second-line treatment of squamous non-small cell lung cancer.]Filippo De Marinis, Antonio Passaro
Pageof 34